A phase II randomised prospective study comparing Interleukin-2 versus Interleukin-2 with SRL 172 in patients with Advanced Renal Cell Carcinoma.
Phase of Trial: Phase II/III
Latest Information Update: 16 Jun 2016
At a glance
- Drugs IMM-201 (Primary) ; Interleukin-2
- Indications Renal cell carcinoma
- Focus Therapeutic Use
- 13 Feb 2016 United Kingdom Clinical Research Network reports accrual to date as 46%.
- 12 Feb 2016 Status changed from active, no longer recruiting to completed as reported by United Kingdom Clinical Research Network record.
- 18 May 2010 New trial record